What this is
- How it works
- How it works isn't classified yet
- Tested for
- Vocal Fold Scar
- Main trialPhase 3
- “The purpose of this study is to confirm the efficacy and safety of KP-100LI, a intracordal formulation containing recombinant human dHGF as the active pharmaceutical ingredient, for voice function improvement therapy in patients with vocal fold scar (including vocal fold sulcus).”In the company’s words, NCT05627648 on ClinicalTrials.gov
- Other names
- Hepatocyte Growth Factor · HGF
Other drugs for Vocal Fold Scar
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Jul 2026 | Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026